The DGCI has approved Bharat Biotech's COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
Covaxin is currently being administered to the people in the country along with Covishield. Hyderabad-based Bharat Biotech is manufacturing Covaxin.
Serum Institute and Bharat Biotech have submitted to the Centre that they can ramp up production of Covishield and Covaxin to 10 crore and 7.8 crore doses, respectively, by August.
Several Covid-19 vaccination centres in Delhi are closed due to shortage of vaccine. Manish Sisodia has claimed that Covaxin manufacturer Bharat Biotech has declined to provide vaccine.
Bharat Biotech co-founder and Joint MD Suchitra Ella tweeted this on Wednesday amid reports of some states voicing their unhappiness over supplies.
Vaccine maker Bharat Biotech will soon begin the clinical trial for those falling between the age of 2-18 years old.
BIBCOL will manufacture 2 crore doses of Covaxin every month at its Bulandshahar plant in Uttar Pradesh.
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
Government has said that a tweet claiming that Covaxin has been approved for children above 12 years of age is fake.
The company is supplying vaccines to Andhra Pradesh, Assam, Chhattisgarh, Gujarat, Jammu & Kashmir, Jharkhand, Madhya Pradesh, Odisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal.
Serum Institute of India CEO Aadar Poonawalla has said that the production of COVID-19 vaccine Covishield is in full swing in Pune and he will review the operations once he is back in the country.
Covaxin vaccine maker Bharat Biotech on Thursday announced a drop in the price of its vaccine that will be made available to the state governments.
Maharashtra remains one of the worst-COVID-affected states in the country. As many as 66,358 new cases, 895 deaths and 67,752 recoveries were reported on Tuesday. The total case tally stands at 44,100,85.
The move has come days ahead of India's planned drive to inoculate all aged above 18. The vaccination drive is set to begin May 1.
Bharat Biotech has written to India's drug regulator seeking extension of the shelf-life of its indigenously developed COVID-19 vaccine Covaxin from six to 24 months, sources said on Sunday.
Covaxin, India's indigeniously developmed coronavirus vaccine, will be sold at Rs 600 per dose for state hospitals and Rs 1,200 per dose for private hospitals, vaccine maker Bharat Biotech has informed.
Govt Principal Secy (Covid Management and Vaccination) wrote letters to Bharat Biotech MD Krishna Yella and Serum Institute of India Limited CEO Adar Poonawalla in this regard.
The Biden administration has conveyed to India that they understand India's pharmaceutical requirements and has promised to review embargo on Covid-19 vaccine raw material.
COVID-19 vaccine: SII will supply 200 million doses and Bharat Biotech is to supply another 90 million doses to the government by July at a pre-agreed rate of Rs 150 per dose.
The expert panel of India's drug regulator, DCGI, has permitted Bharat Biotech to give the third dose of Covaxin to a few volunteers in its clinical trials of the COVID-19 vaccine.
Top News
Latest News
